Adar1 Capital Management, LLC and Daniel Schneeberger
Filed with the SEC on · accession 0001104659-26-097425
RNTX filed a SCHEDULE 13G (schedule 13g) with the SEC on Aug 14, 2026. A report the company filed with the SEC (the US market regulator). The stock moved +2.3% by the first close after the filing.
Adar1 Capital Management, LLC and Daniel Schneeberger filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Rein Therapeutics, Inc. common stock.
Close before
$0.79
Aug 13, 2026
First close after
+2.35%
$0.81
5 trading days
+0.77%
$0.79
Since filing
-22.07%
$0.61
✦ Ask GOAX AI about this filing — what it means for RNTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for RNTX?
Click hereRNTX filed a SCHEDULE 13G (SEC filing). Adar1 Capital Management, LLC and Daniel Schneeberger filed a Schedule 13G joint filing agreement regarding their beneficial ownership of Rein Therapeutics, Inc. common stock.
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
RNTX closed at $0.79 before the filing and $0.81 on Aug 14, 2026 (+2.35%). Five trading days later: $0.79 (+0.77%).
Get alerts when RNTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days